Cell and Gene Therapy Manufacturing QC Market is Expected to Drive Growth at a CAGR of 22.80% between 2020 and 2030

The global cell and gene therapy manufacturing QC market held a value of $574.8 million. The market is expected to grow at a CAGR of 22.80% during the forecast period 2020-2030 and attain a value of $5.92 billion by 2030. The growth in this market is primarily attributed to the rise in prevalence of cancer and chronic diseases and increase in investment from big pharma companies. In addition, the entry of several established players from the biomanufacturing market, such as Lonza AG and Merck KGaA, as well as diversification of product and service offerings among analytical testing juggernauts such as Charles River Laboratories International, Inc. and Eurofins Scientific SE, is aiding in tremendous market growth.

Market Segmentation

• Product – Services and Products (Kits and Assays, Instruments, Reagents, and Software)

• Process – Starting Material Preparation, Upstream Processing, and Downstream Processing

• Analytical Methods – Safety Testing, Purity Testing, Potency Testing, Identity Testing, and Stability Testing

• Technology – Polymerase Chain Reaction (PCR), Flow Cytometry, Limulus Amebocyte Lysate (LAL), Enzyme-Linked Immunosorbent Assay (ELISA), Chromatography, Mass Spectrometry, Western Blotting, Next-Generation Sequencing (NGS), and Electrophoresis, among others

Regional Segmentation

• North America – U.S., and Canada

• Europe – Germany, U.K., France, Italy, Spain, Netherlands, Russia, and Rest-of-Europe

• Asia-Pacific – China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific

• Latin America – Brazil, Mexico, and Rest-of-Latin America

• Rest-of-the-World

Growth Drivers

• Increasing Prevalence of Cancer and Chronic Diseases

• Rising Number of Clinical Trials

• Steady Investment and Consolidation in the Cell and Gene Therapy Market

• Favorable Regulatory Environment

Market Challenges

• Lack of Reliable Vector Production for Cell and Gene Therapy

• Lack of Therapy Specific Assays

Market Opportunities

• Drug Approvals and Strong Pipeline of Cell and Gene Therapies

• Multiple Investments in Expansion of cGMP Units

Key Companies Profiled

bioMérieux SA, Bio-Techne Corporation, Catalent, Inc., Charles River Laboratories International, Inc., Eurofins Scientific S.E., F. Hoffmann-La Roche Ltd., Intertek Group plc, Lonza Group AG, Merck KGaA, Sartorius AG, SGS S.A, Thermo Fisher Scientific Inc., WuXi AppTec, Sistemic Scotland Limited, and Vigene Biosciences, Inc.

Request a Sample - https://bisresearch.com/requestsample?id=1071&type=download

Comments

Microbiome Therapeutics Market Growth, Segmentation, Opportunity and Forecast to 2032

Global microbiome therapeutics market is expected to grow further in the coming years due to the continuous increase in awareness and need for better and safer treatment alternatives and the dominance of gastrointestinal (GI) and infectious diseases segment can be attributed to the existing dominance of microbiome therapeutics available for a variety of indications ranging from diarrhea and gut dysbiosis to skin disorders, cancer indications among others. The global microbiome therapeutics market which accounted for $306.3 million in 2021 is expected to reach $3,204 million by 2032, reporting a CAGR of 24.95% during the forecast period 2022-2032. The existing microbiome therapeutics market is favored by multiple factors, including the rising geriatric populations coupled with the increasing adoption of inorganic growth strategies by key players in the market. Impact of COVID-19 There were numerous consequences due to the COVID-19 pandemic, especially...

PD-1/PDL-1 Inhibitor Market Growth Prospects, Emerging Trends and Forecast to 2032

PD-1/PDL-1 inhibitors are immune-therapeutic agents used in the treatment of various cancer indications, mostly in the advanced stages. PD-1/PDL-1 inhibitors are monoclonal antibodies majorly of IgG1 and IgG4 types to be administered to patients via injection The current market already has seven approved products in the U.S. and a large number of research activities are currently undergoing in this segment generating interest of commercial as well as academic research institutions. In the current period of precision medicine and providing targeted treatment, identification of target patient has become very important as well as complicated. With the emergence of diagnostic test identifying predictive biomarkers, the selection and administration of targeted treatment has become comparativlely conveninent and efficient. PD-1/PDL-1 inhibitors market are majorly indicated for the treatment of advanced cases of different cancer indications. The PD-1/PDL-1 inibitor treatment has ...

Clinical Decision Support Systems (CDSS) Market registering a CAGR of 6.70% during the forecast period 2021-2030

The global market for clinical decision support systems (CDSS) registered the market value of $1,918.8 million in 2020 and is expected to reach $3,739.2 million by 2030, registering at a CAGR of 6.70% during the forecast period 2020-2030. The clinical decision support systems of the future are expected to be developed to leverage data to make observations which are not interpretable by humans. Healthcare IT systems in the future are expected to leverage cutting-edge technology as an enabler to make clinical care more streamlined and accurate. The technology is still in its nascent stage. One of the strong points of this technology is that it improves with time. Continuous input from clinicians, patients, and other stakeholders will be essential for correctly implementing the technology to enhance meaningful uses, reduce costs, and improve treatment outcomes. Key USPs of the Report Following are some of the key contents of the report: • Industry Analysis ...

Market Research Reports

Search This Blog